Unknown

Dataset Information

Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity.


ABSTRACT:

Background

HSG4112 is a clinical-stage drug candidate for the treatment of obesity. Here, we report its discovery and preclinical efficacy.

Methods

In high-fat diet (HFD)-induced obese male C57BL/6J mice, we tested the weight loss effect of synthetic compounds derived from a structure-activity relationship (SAR) study of glabridin, a natural compound known to reduce body weight and influence energy homeostasis. After selecting HSG4112 as our optimized compound from this discovery method, we characterized its pharmacological effects on parameters related to obesity through in vivo metabolic and biochemical measurements, histology and gene expression analysis, and indirect calorimetry.

Results

Through the SAR study, we identified four novel components of glabridin perti

SUBMITTER: Choi LS 

PROVIDER: S-EPMC7752758 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature